Please login to the form below

Not currently logged in
Email:
Password:

Boehringer in antibody partnership

Boehringer Ingelheim has signed a deal with MacroGenics to develop therapies based on MacroGenics' antibody technology platform

Boehringer Ingelheim has signed a deal with the privately held biotechnology company MacroGenics to develop and commercialise therapies based on MacroGenics' antibody technology platform.

Under the global alliance, the companies will work together to discover, develop and commercialise therapeutics in areas such as immunology, oncology, respiratory, cardiometabolic and infectious diseases. The drug candidates will be based on MacroGenics' Dual-Affinity Re-Targeting (DART) biospecific antibody technology platform and will be directed against up to 10 combinations of molecular targets.

The companies will have joint responsibility for discovery and some preclinical activities, with Boehringer Ingelheim taking full responsibility for all subsequent preclinical, clinical, regulatory, commercial and manufacturing activities.

MacroGenics will likely receive about $60m during the first several years of the partnership, with that figure consisting of an upfront cash payment, annual maintenance fees, R&D funding, and near-term research-based milestones. The company also stands to receive milestone payments that could theoretically total $210m for each of the 10 development programmes in case of full commercial success of multiple DART products.

The deal calls for MacroGenics to receive tiered royalties on net product sales and gives the company the option to co-promote certain DART products in the US. In addition, as the partnership progresses, Boehringer Ingelheim also expects to make an equity investment in the company.

MacroGenics, which was founded about a decade ago, is based in Rockville, Maryland. The company's lead product is teplizumab, an antibody that is in phase III trials for the treatment of autoimmune diseases under a partnership with Lilly.

27th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics